News | March 31, 2008

Spirit II Results Support Boston Scientific’s Drug-Eluting Stent Platform

April 1, 2008 – Boston Scientific welcomed results from Abbott’s prospective, randomized, single blind, two-year SPIRIT II Trial, comparing the safety and efficacy of the XIENCE V (PROMUS) Everolimus-Eluting Coronary Stent and Boston Scientific’s TAXUS Express Paclitaxel Eluting Coronary Stent System in 300 patients in Europe.

The PROMUS Stent is a private-label XIENCE V manufactured by Abbott and distributed by Boston Scientific.

The results, presented yesterday at ACC 2008, demonstrated no numerical differences between the XIENCE V and the TAXUS in their angiographic outcomes. The cardiac death rate at two years for the XIENCE V was .5 percent and for the TAXUS was 1.4 percent. Myocardial infarction (MI) rates at two years for the XIENCE V and TAXUS were 2.8 percent and 5.5 percent, respectively.

The XIENCE V (PROMUS) Stent is currently pending approval by the FDA, which is expected to occur in the first half of 2008, said Boston Scientific.

For more information: www.bostonscientific.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Tryton Medical, Side Branch Stent, first U.S. commercial case, New York-Presbyterian Hospital, Columbia University Medical Center
News | Stents Bifurcation| March 31, 2017
Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch Stent was...
Sponsored Content | Videos | Stents Bioresorbable| March 30, 2017
Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses t
Overlay Init